These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 16153448

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE, Rundall BK, Keller MD, Jones DR.
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
    Kim MK, Jeon YK, Woo JK, Choi Y, Choi DH, Kim YH, Kim CW.
    Mol Cancer; 2011 Aug 16; 10():98. PubMed ID: 21843371
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
    Zheng L, Fu Y, Zhuang L, Gai R, Ma J, Lou J, Zhu H, He Q, Yang B.
    Int J Cancer; 2014 Oct 01; 135(7):1721-32. PubMed ID: 24615207
    [Abstract] [Full Text] [Related]

  • 7. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G, Gekeler V, Leja A, Beckers T, Boehm M.
    Cancer Res; 2006 May 15; 66(10):5409-18. PubMed ID: 16707469
    [Abstract] [Full Text] [Related]

  • 8. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
    Arnold NB, Arkus N, Gunn J, Korc M.
    Clin Cancer Res; 2007 Jan 01; 13(1):18-26. PubMed ID: 17200334
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 01; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
    Jones DR, Broad RM, Madrid LV, Baldwin AS, Mayo MW.
    Ann Thorac Surg; 2000 Sep 01; 70(3):930-6; discussion 936-7. PubMed ID: 11016336
    [Abstract] [Full Text] [Related]

  • 11. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR, Han BR, Park WH.
    Oncotarget; 2017 Mar 14; 8(11):17726-17737. PubMed ID: 28099148
    [Abstract] [Full Text] [Related]

  • 12. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation.
    Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB.
    J Biol Chem; 2006 Mar 03; 281(9):5612-22. PubMed ID: 16377638
    [Abstract] [Full Text] [Related]

  • 13. Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
    Jeon HG, Yoon CY, Yu JH, Park MJ, Lee JE, Jeong SJ, Hong SK, Byun SS, Lee SE.
    J Urol; 2011 Nov 03; 186(5):2084-93. PubMed ID: 21944112
    [Abstract] [Full Text] [Related]

  • 14. Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
    Hanke NT, Garland LL, Baker AF.
    J Cancer Res Clin Oncol; 2016 Mar 03; 142(3):549-60. PubMed ID: 26385374
    [Abstract] [Full Text] [Related]

  • 15. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, Del Tacca M.
    Br J Cancer; 2005 Feb 28; 92(4):681-9. PubMed ID: 15700043
    [Abstract] [Full Text] [Related]

  • 16. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR.
    J Thorac Cardiovasc Surg; 2004 Apr 28; 127(4):1078-86. PubMed ID: 15052205
    [Abstract] [Full Text] [Related]

  • 17. Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Lee JK, Ryu JK, Yang KY, Woo SM, Park JK, Yoon WJ, Lee SH, Jeong KS, Kim YT, Yoon YB.
    Pancreas; 2011 Aug 28; 40(6):966-73. PubMed ID: 21487323
    [Abstract] [Full Text] [Related]

  • 18. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.
    PLoS One; 2010 Sep 14; 5(9):e12417. PubMed ID: 20856855
    [Abstract] [Full Text] [Related]

  • 19. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
    Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C.
    Mol Cancer Ther; 2007 Jan 14; 6(1):37-50. PubMed ID: 17237265
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation.
    Jones DR, Broad RM, Comeau LD, Parsons SJ, Mayo MW.
    J Thorac Cardiovasc Surg; 2002 Feb 14; 123(2):310-7. PubMed ID: 11828291
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.